Liver Cancer Pipeline Market 2022 Research Report: Comprehensive Information on 75+ Companies and 75+ Drugs in Pipeline –

DUBLIN–(BUSINESS WIRE)–The “Liver Cancer – Pipeline Overview, 2022” clinical trials have been added to from offer.

This Liver Cancer – Pipeline Insight, 2022 report provides comprehensive insights on 75+ companies and 75+ drugs in development in the liver cancer pipeline landscape.

It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

A detailed picture of the Liver Cancer pipeline landscape is provided, which includes the disease overview and Liver Cancer treatment guidelines. The assessment part of the report includes an in-depth Liver Cancer business assessment and clinical evaluation of the pipeline products under development.

In the report, a detailed description of the drug is given including the mechanism of action of the drug, clinical studies, NDA approvals (if any) and product development activities including technology, cancer collaborations liver, licensing, mergers and acquisitions, financing, designations and other product-related details.

Report Highlights

Companies and academics are scrambling to assess challenges and seek out opportunities that can influence liver cancer R&D. The therapies under development are focused on new approaches to treat/improve liver cancer.

As of May 2022, SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses in NSCLC, RCC and HCC. Confirmed partial responses (PR) were observed in two patients who received SRF388 monotherapy treatment: one in non-small cell lung cancer (NSCLC) (previously reported) and one in clear cell renal cell carcinoma ( CCR). Additionally, PR was observed in a patient treated with SRF388 in combination with pembrolizumab for hepatocellular carcinoma (HCC).

In February 2021, the United States Food & Drug Administration (FDA) granted Kintor Pharma an Investigational New Drug (IND) application for the ALK-1 antibody as a second-line treatment for HCC.

This segment of the Liver Cancer report contains its detailed analysis of various drugs at different stages of clinical development including Phase II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Emerging liver cancer drugs

SRF388: Surface oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface oncology has identified particular tumor types, including liver, kidney and lung cancer, where IL-27 appears to play an important role in the immunosuppressive microenvironment of the tumor and may contribute to resistance to treatment with checkpoint inhibitors.

SRF388 targets the limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks the immunosuppressive biological effects of IL-27, resulting in the activation of immune cells in combination with other cancer therapies, including anti-PD-1 therapy, as well as strong anti-tumor effects as monotherapy.

MTL-CEBPA: MiNA Therapeutic

MTL-CEBPA is a new drug originally developed as a combination cancer therapy. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring protein C/EBP-a to normal levels using the RNA activation mechanism.

APX3330: Ocuphire Pharma

ALK-1 Antibody is a first-in-class, fully human IgG2 neutralizing monoclonal antibody that inhibits BMP9, TGF-b via ALK-1 receptor-mediated signal transduction and tumor angiogenesis.

Fostroxacitabine bralpamide: Medivir

Fostroxacitabine bralpamide (also called MIV-818) is a prodrug designed to selectively treat liver cancers and minimize side effects. It has the potential to become the first orally-administered liver-targeting drug for patients with HCC and other forms of liver cancer.

CDX-527: Celldex Therapeutics

CDX-527 is a bispecific antibody composed of Celldex’s proprietary human PD-L1 and CD27 antibodies. CDX-527 combines PD-1 pathway blockade with T cell costimulation via CD27 in a single molecule using an IgG1-ScFv format. Preclinical data demonstrates that CDX-527 is more potent than the combination of anti-PD-L1 and anti-CD27 antibodies in T-cell activation and anti-tumor activity. CDX-527 has direct antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing CD27 or PD-L1. Additionally, CDX-527 exhibits an antibody-like pharmacokinetic profile without any toxicity of concern in preclinical models.

Liver cancer: therapeutic assessment

This segment of the report provides Liver Cancer Drugs information separated based on the following parameters that define the scope of the report such as:

Main players in liver cancer

Approx. Over 75 key companies developing liver cancer therapies. Companies with liver cancer drug candidates in the most advanced stage, i.e. Phase III, include Polaris Group.


  • Late-stage products (Phase III)

  • Intermediate products (Phase II)

  • Produced at an early stage (Phase I) as well as details of

  • Candidates in the preclinical and discovery phase

  • Abandoned and Inactive Candidates

  • Route of administration

The Liver Cancer Pipeline report provides the therapeutic evaluation of pipeline drugs by route of administration.

Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Molecule type

The products have been categorized under different types of molecules such as

  • Monoclonal antibody

  • peptides

  • Polymer

  • small molecule

  • Immunotherapy

  • type of product

Drugs have been categorized into different product types like Mono, Combination and Mono/Combination.

Liver cancer: pipeline development activities

The report provides an overview of different therapeutic candidates in phase II, I, preclinical and discovery. It also analyzes key Liver Cancer Therapeutic Drug players involved in key drug development.

Pipeline development activities

The report covers the detailed information on collaborations, acquisitions and mergers, licenses as well as in-depth therapeutic evaluation of emerging liver cancer drugs.

Overview of Liver Cancer Report

  • Liver cancer analysis

  • Therapeutic assessment

  • Unmet needs

  • Impact of drugs

Liver Cancer Report Assessment

  • Pipeline Product Profiles

  • Therapeutic assessment

  • Pipeline assessment

  • Evaluation of inactive drugs

  • Unmet needs

Key players

  • Shanghai Henlius Biotech

  • Boehringer Ingelheim

  • Bristol Myers Squibb

  • Jiangsu Hengrui Medicine

  • Glaxo SmithKline

  • ZAI Laboratory

  • Beijing Immunochina Medical Science and Technology

  • MiNA Therapeutic

  • Abbisko Therapeutic

  • Medivir AB

  • Teclison

  • Genoscience

  • Therapeutic Eureka

  • Celsion Corporation

  • H3 Biomedicine

  • TriSalus Life Sciences

  • Celldex therapeutics

  • Takeda

  • Biomedical company Megapro

  • Polaris Group

Key players

  • Ezabenlimab

  • Relatlimab

  • Camrelizumab

  • Cobolimab

  • brivanib alaninate

  • MI 83


  • ABSK 011

  • fostroxacitabine bralpamide

  • Tirapazamine

  • GNS561

  • ET 1402L1-CART

  • NIK-333

  • Liposomal doxorubicin

  • H3B 6527

  • SD-101

  • CDX-527

  • TAK-500

  • m-PEG iron oxide nanoparticle

  • ADI-PEG20

For more information on this clinical trial report, visit

Comments are closed.